WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
Executive Summary TScan’s presentation focused on two main programs: its hematologic malignancies (HEME) program, which has shown promising Phase 1 data, and its solid tumor program utilizing a ...
TScan Therapeutics Inc. (NASDAQ:TCRX), a biotechnology company specializing in T-cell receptor (TCR) engineered T cell therapies, stands at a critical juncture in its development pipeline. With key ...
Data from ALLOHA™ Phase 1 heme trial to be presented at the 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Made the strategic decision to prioritize clinical development of ...
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T ...
Potential TScan Therapeutics, Inc. (NASDAQ:TCRX) shareholders may wish to note that the Chairman of the Board, Timothy Barberich, recently bought US$142k worth of stock, paying US$4.89 for each share.
WALTHAM, Mass., May 26, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results